Dr Langsjoen CoQ10 presentation at ICQA 2022 Hamburg Conference – 40 Years of unmatched CoQ10 Research and Clinical Practice for Heart Failure

Dr. Peter Langsjoen, the world’s foremost expert on CoQ10 in cardiac diseases, gave a milestone presentation at the ICQA 2022 Hamburg Conference. His presentation titled “Practical Use of CoQ10 in Heart Failure Including Statin-Associated Cardiomyopathy” covered a lot of unpublished experience and information that will be beneficial to those seeking to improve their cardiovascular health.

Background and Introduction

Dr. Langsjoen has over 40 years of clinical and research experience with CoQ10, and his presentation at ICQA22 was a culmination of his life’s work. During the presentation, Dr. Langsjoen shared his expertise on the role of CoQ10 in heart failure, including its use in treating statin-associated cardiomyopathy.

Dr Langsjoen CoQ10 presentation key takeaways

Dr. Langsjoen highlighted the essential role of CoQ10 in mitochondrial function and its impact on overall health. He mentioned that 2.5 μg CoQ10/ml plasma level was previously considered the target for CVD therapeutic effect, but he now suggests that up to 6 μg/ml may be required. He also mentioned that either form of CoQ10 works.

Dr. Langsjoen discussed his experience with CoQ10 supplementation in the treatment of heart failure, which has been highly gratifying and free of adverse effects. However, he noted that Q10 supplementation in HF may require gradually decreasing beta-blockers, angiotensin-converting enzyme inhibitors, and diuretics to avoid hypotension and similar effects.